Inventiva's FY2025 Results Confirm Runway but Amplify Burn and Dilution Risks

What happened

Inventiva released its audited FY2025 financial results on March 30, 2026, reporting cash and short-term deposits totaling €230.9 million, which aligns with prior guidance and extends the runway into early 2027. Operating cash burn increased to €104.6 million, up 22% from 2024, driven by ongoing NATiV3 Phase 3 trial costs and corporate overhead. The business update reiterated NATiV3's progress with no new safety signals, maintaining the topline data timeline for 2H 2026. However, negative equity and persistent high burn underscore the company's reliance on external financing, highlighting structural dilution risk. Investors must now scrutinize trial retention rates and competitive pressures as the pivotal readout approaches.

Implication

With runway secured through early 2027, the immediate financing overhang is alleviated, shifting focus to NATiV3's operational integrity, particularly discontinuation rates below 30% before Week 72. The 22% increase in cash burn to €104.6 million signals ongoing high costs, necessitating vigilance on future capital raises that could dilute equity. Competitive dynamics intensify as Rezdiffra's commercial traction and Wegovy's approval raise efficacy benchmarks, pressuring lanifibranor's positioning. Investors should maintain a WAIT stance, considering entry only after verifying stable trial signals and manageable cash use in upcoming quarterly updates. The investment remains a high-risk, single-asset bet, with all value hinging on flawless trial execution and positive 2H 2026 data.

Thesis delta

The FY2025 results validate the cash runway assumption, slightly de-risking the financing component that was a key uncertainty. However, the core thesis remains unchanged: Inventiva is a binary option on NATiV3's success, with no shift in the WAIT rating as trial integrity and competitive risks persist unabated.